Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715396 | 0.93 | SCN9A (0.48) | SCN9AKCNB1SCN3AROCK2ADORA2A | |
| SCHEMBL2714516 | 0.93 | SCN9A (0.49) | SCN9AKCNB1CARM1PRMT6ROCK2 | |
| SCHEMBL2716384 | 0.90 | SCN9A (0.53) | SCN9AKCNB1SCN3AROCK2 | |
| SCHEMBL2717997 | 0.90 | RIPK1 (0.43) | P2RX7SCN3ACHRM4ROCK2RIPK1 | |
| SCHEMBL2714916 | 0.87 | EPHX2 (0.53) | SCN9AKCNB1PDE2A | |
| SCHEMBL18266303 | 0.86 | SCN9A (0.47) | SCN9AKCNB1CHRM4ROCK2RIPK1 | |
| SCHEMBL2718447 | 0.86 | MAPT (0.46) | SCN9AKCNB1CHRM4CARM1PRMT6 | |
| SCHEMBL2715370 | 0.86 | MAPT (0.51) | SCN9AKCNB1P2RX7CACNA1HSCN3A | |
| SCHEMBL18266643 | 0.84 | SCN9A (0.46) | SCN9AADORA2AADORA1 | |
| SCHEMBL2715135 | 0.84 | KCNB1 (0.56) | SCN9AKCNB1ROCK2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | claimed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | claimed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | claimed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | claimed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | claimed |
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | SCN9A 31/4885KCNB1 15/4885P2RX7 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.